Bio-Rad Laboratories BIO Effect of exchange rate changes on cash, cash equivalents and restricted cash

Effect of exchange rate changes on cash, cash equivalents and restricted cash at other companies

Charles River LaboratoriesCRL

$1.25M-76.3%

RevvityRVTY

——

GE HealthCare TechnologiesGEHC

——

ZoetisZTS

——

Other financials

Income statement

See full

Revenue$592.1M+1.1%

Gross profit$309.4M+1.1%

Operating income$34.1M+43.9%

Net income-$527.1M-924%

EPS (diluted)-$19.55-954%

Balance sheet

See full

Cash & equivalents$509.0M-2.7%

Total debt$987.3M-28.4%

Total equity$6.9B+2.6%

Total assets$9.8B+2.8%

Cash flow

See full

Operating cash flow$108.1M-16.8%

CapEx$30.0M-12.8%

Free cash flow$78.1M-18.2%

Valuation

See full

Market cap$7.56B+10.3%

Enterprise value$8.04B+4.2%

P/E44.8×—

P/S2.9×+0.2×

Profitability

See full

Gross margin51.9%-1.6pp

Operating margin8.8%-3.1pp

Net margin6.5%+3.4pp

FCF margin13.8%-0.2pp

Returns & leverage

See full

Return on equity2.5%+1.3pp

Debt / equity0.1×-0.1×

Current ratio3.2×-2.8×

Where this comes from

Reported directly by Bio-Rad Laboratories in its filing.

Tagged under the XBRL concept us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bio-Rad Laboratories's effect of exchange rate changes on cash, cash equivalents and restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bio-Rad Laboratories's effect of exchange rate changes on cash, cash equivalents and restricted cash?: Bio-Rad Laboratories (BIO) reported effect of exchange rate changes on cash, cash equivalents and restricted cash of $5.9M in Q1 2026.
How has Bio-Rad Laboratories's effect of exchange rate changes on cash, cash equivalents and restricted cash changed year-over-year?: Bio-Rad Laboratories's effect of exchange rate changes on cash, cash equivalents and restricted cash increased by 427.8% year-over-year, from -$1.8M to $5.9M.